AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00331123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo patch,changed every 3-4 days for 24 weeks during double blind phase
Study NCT01052896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 300mg po TID
Study NCT01052896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look-alike of gabapentin 300mg given po tid
Study NCT02761551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder notifications via autodialer
Study NCT04029116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: 150 mg every 72 hours for 3 doses
Study NCT04029116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluconazole Tablet
Description: 150 mg every 72 hours for 3 doses
Study NCT04029116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBREXAFUNGERP
Description: 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
Study NCT04029116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: BID (one day) every 4 weeks for a total of 6 dosing days
Study NCT01672034 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic gastric bypass surgery
Study NCT03606980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Dexamethasone sodium phosphate administered via iontophoresis
Study NCT03606980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Iontophoresis on affected knee
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2 i.v.
Description: 3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 s.c.
Description: 0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
Study NCT03606980 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoresis
Description: Iontophoresis on affected knee
Study NCT03606980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy of affected knee
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Description: 160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinoic acid
Description: 160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
Study NCT03606980 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy of affected knee
Study NCT03606980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy of affected knee
Study NCT04084964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-hospitalisation platform for heart failure
Description: The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
Study NCT01961661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month
Study NCT01961661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months
Study NCT00524849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zometa 1 mg weekly (intravenous)
Study NCT00524849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zometa 4 mg every four weeks (intravenous)
Study NCT03107871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
Study NCT03107871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simple Syrup
Description: Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
Study NCT04195165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX
Description: The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.
Study NCT01493908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High price
Description: Acetaminophen label as high price
Study NCT01493908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low price
Description: Acetaminophen label as low price
Study NCT01493908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low price participants aware paying part
Description: Acetaminophen label as low price; participants aware they are paying part of the full price
Study NCT01493908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No price
Description: acetaminophen. No price - price issue not introduced to participants.
Study NCT01493908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Free of charge
Description: Acetaminophen. participants aware the product is free of charge
Study NCT01316653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW Healthier
Description: Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
Study NCT01316653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW Smarter
Description: Group sessions that meet six times over the course of three years with quarterly newsletters.
Study NCT01316653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GROW Smarter
Description: Group sessions that meet six times over the course of three years with quarterly newsletters.
Study NCT00936286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpiroTiger
Description: Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
Study NCT04467203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadanafil
Description: Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting->~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting
Study NCT01532986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated care management for Parkinson's disease
Description: Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
Study NCT01532986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coordinated care management for Parkinson's disease
Description: Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
Study NCT01532986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational handout
Description: To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise.
Study NCT03303976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioconjugate pneumococcal vaccine
Description: Bioconjuagte vaccine against bacterial pneumococcal infection
Study NCT03303976 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Multivalent plain polysaccharide vaccine
Description: Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
Study NCT02604394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rheolytic Thrombectomy
Description: RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~1. The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~2. The disposable pump connects to a bag of heparinized saline.~3. The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,
Study NCT02604394 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional PCI
Description: In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
Study NCT02604394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
Study NCT03272763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Toffee mask
Description: Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
Study NCT04458103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous RVAD
Description: ProtekDuo or Impella RP
Study NCT01458704 — intervention group
Intervention type: OTHER
Intervention: next generation sequencing
Description: next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
Study NCT03079232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCTAV Patient
Description: In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
Study NCT03079232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCTAV Control group
Description: In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
Study NCT02292966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BCV
Description: Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
Study NCT01974388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG started 2 cm from the pylorus
Description: Laparoscopic sleeve gastrectomy started 2 cm from pylorus
Study NCT01974388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG started 6 cm from pylorus
Description: LSG started 6 cm from pylorus
Study NCT03201913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTC-352
Description: Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
Study NCT02607449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS-1
Description: FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
Study NCT02607449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without any active pharmaceutical ingredients
Study NCT03139708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alphagan
Description: Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
Study NCT03139708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one.
Study NCT03139708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one.
Study NCT03139708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one.
Study NCT03139708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tropicamide
Description: Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one.
Study NCT00356616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trizivir (AZT+3HT+Abacavir) twice daily
Description: Trizivir (AZT+3HT+Abacavir) twice daily
Study NCT00356616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread (300 mg Tenofovir disoproxil fumarate) once daily
Description: Viread (300 mg Tenofovir disoproxil fumarate) once daily
Study NCT00894686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
Description: Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
Study NCT03059927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty, Cruciate retaining
Description: Legion total knee arthroplasty implant component, Smith \& Nephew, Cruciate Retaining design
Study NCT03059927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty, Anterior stabilized
Description: Legion total knee arthroplasty implant component, Smith \& Nephew, Anterior Stabilized design
Study NCT03059927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty, Posterior stabilized
Description: Legion total knee arthroplasty implant component, Smith \& Nephew, Posterior Stabilized design
Study NCT00943020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutricia PreOp nutritional supplement
Description: nutritional supplement
Study NCT00943020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia PreOp nutritional supplement
Description: nutritional supplement
Study NCT00943020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipid
Description: Drink
Study NCT00943020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Drink
Study NCT02341703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole-metformin
Description: letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
Study NCT02341703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole-metformin-pioglitazone
Description: letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
Study NCT02341703 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound
Description: transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
Study NCT02341703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory investigations
Description: day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
Study NCT04119141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X ray imaging
Description: Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions.
Study NCT04119141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: X ray imaging
Description: Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions.
Study NCT01923350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Reduction Intervention
Description: The weight trial intervention components were:~* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~* Print mailings/emailings~* 3 Get Ready e-messages in the four weeks before the weight intervention began~* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals.
Study NCT01923350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Reduction Control Arm
Description: Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
Study NCT01923350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tested for diabetes
Description: Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
Study NCT01923350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Not tested for diabetes
Description: Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
Study NCT03948360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Irradiance Monochromatic Biostimulation (LIMB) Device
Description: The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.